Document Detail


Clinical tumour markers in lung cancer.
MedLine Citation:
PMID:  7539317     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Within the past few years, the measurement of serum and tissue markers has had an increasing influence on clinical decisions about initial treatment and follow-up. Lung cancer illustrates the types and importance of these various markers. This review presents data concerning the most studied and interesting markers in non-small cell (NSCLC) and small cell lung cancer (SCLC). CEA, TPA, SCC-Ag, CYFRA 21-1, ferritin, CA19-9, CA50, CA242, H-K-N-ras mutations and p53 mutation seem to be the most prolific in NSCLC, while NSE, BN/GRP, CK-BB, NCAM, IL-2R, IGF-I, transferrin, ANP, mAb (cluster 5), Le-y and c-N-L-myc mutation are markers in SCLC patients. Some of these serum markers might be useful adjuncts for monitoring response to therapy, including early detection of tumour reactivation to allow curative therapy and rapid detection of treatment failure to allow change of the regimen. The study of these markers also may lead to a better understanding of the biological characteristics of lung cancer. The information derived from these biological studies represents the most promising avenue towards new treatment strategies, as well as attempts at secondary prevention.
Authors:
J Niklinski; M Furman
Related Documents :
11224607 - Immunoreactivity for thyroid transcription factor-1 in stage i non-small cell carcinoma...
9626477 - The growth inhibitory effect of n1,n12-bis(ethyl)spermine in small cell lung cancer cel...
8214927 - Neural cell adhesion molecule and prognosis of surgically resected lung cancer.
17581297 - Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not t...
10874487 - E-cadherin, estrogens and cancer: is there a connection?
22785007 - Population-based hormone receptor-specific incidence trends of breast cancer in germany.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)     Volume:  4     ISSN:  0959-8278     ISO Abbreviation:  Eur. J. Cancer Prev.     Publication Date:  1995 Apr 
Date Detail:
Created Date:  1995-06-30     Completed Date:  1995-06-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9300837     Medline TA:  Eur J Cancer Prev     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  129-38     Citation Subset:  IM    
Affiliation:
Department of Thoracic Surgery, Medical School, Bialystok, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, Neoplasm / blood
Carcinoembryonic Antigen / blood
Carcinoma, Non-Small-Cell Lung / blood*,  genetics
Carcinoma, Small Cell / blood*
Genes, p53
Genes, ras
Humans
Keratins / blood
Lung Neoplasms / blood*,  genetics
Peptides / blood
Phosphopyruvate Hydratase / blood
Tissue Polypeptide Antigen
Tumor Markers, Biological / blood*
Chemical
Reg. No./Substance:
0/Antigens, Neoplasm; 0/Carcinoembryonic Antigen; 0/Peptides; 0/Tissue Polypeptide Antigen; 0/Tumor Markers, Biological; 0/tumor antigen TA-4, human; 68238-35-7/Keratins; EC 4.2.1.11/Phosphopyruvate Hydratase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sarcolemmal indentation in cardiomyopathy with mental retardation and vacuolar myopathy.
Next Document:  Labelling of polysaccharides using [11C]cyanogen bromide. In vivo and in vitro evaluation of 11C-hya...